Anthony Malanga
Pulmonary Disease · Schenectady, NYNPI 1598781320
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 287 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by GSK at 28.6% of the total. Reporting peaked in 2022 at $1,571 and has fallen 90.5% since, to $150 in 2025.
Across 287 payments — averaging $20.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- AstraZeneca$1K
- Boehringer Ingelheim$685
- Sanofi$543
- Regeneron Healthcare Solutions, Inc.$409
- AbbVie$382
- plus $1K from 18 others
What the payments were for
- Food & beverage$5,998100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 95 | $1,716 |
| AstraZeneca | 51 | $1,099 |
| Boehringer Ingelheim | 30 | $685 |
| Sanofi | 17 | $543 |
| Regeneron Healthcare Solutions, Inc. | 15 | $409 |
| AbbVie | 18 | $382 |
| Electromed, Inc. | 8 | $245 |
| Genentech USA, Inc. | 11 | $174 |
| Novartis | 6 | $131 |
| Grifols USA, LLC | 6 | $117 |
| Philips North America LLC | 6 | $101 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $88 |
| Johnson & Johnson | 4 | $67 |
| Insmed, Inc. | 3 | $53 |
| Circassia Inc. | 3 | $37 |
| Actelion Pharmaceuticals US, Inc. | 1 | $24 |
| Paratek Pharmaceuticals, Inc. | 1 | $19 |
| Sunovion Pharmaceuticals Inc. | 2 | $19 |
| Pfizer | 1 | $19 |
| Amgen | 1 | $18 |
| Merck | 1 | $16 |
| Mylan Specialty L.p. | 1 | $13 |
| Advanced Respiratory, Inc | 1 | $12 |
| Nabriva Therapeutics, PLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$262
- DUPIXENT$238
- OFEV$133
- SYMBICORT$106
How this compares
$5,998 in reported general payments places this provider in the 75th percentile of 1,115 pulmonary disease providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Albuterol Sulfate HfaAlbuterol Sulfate | 12 | $583 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Schenectady
- Jehanzeb KhanSchenectady$56K
- Jeffrey WolfGreat Neck$892K
- Keith HarrisPort Jefferson Station$832K
- Jack MannBayside$736K
- Raji AyinlaBronx$673K
- Charles PowellNew York$654K
- Nashat RabadiBuffalo$613K
- Craig ThurmJamaica$604K
- Michael MandelLarchmont$589K
- Sherif El BayadiSyracuse$571K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.